Testing DLL3 CAR-T cells for some brain tumors
Official title: DLL3 CAR-T Therapy Targeting Brain Tumors
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study tests a new cell therapy in people whose brain tumor carries a marker called DLL3.
Read our full plain-language summary
What the trial team says
The purpose of this study is to assess the feasibility, safety and efficacy of Delta-like ligand 3 (DLL3)-specific CAR-T cell therapy in patients with DLL3 positive brain tumors including glioblastomas and diffused intrinsic pontine or midline gliomas (DIPG or DMG). Another goal of the study is to learn more about the function of the anti-DLL3 CAR-T cells and their persistency in patients.
Key facts
- Registry number
- NCT07180927
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- Glioblastoma of Cerebellum
Where it is running
This trial lists 1 site.
-
Guangdong
- Shenzhen Geno-immuno Medical Institute (Shenzhen)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.